Efficacy of fractional co2 laser with PRP in patients with vitiligo
Phase 1
Recruiting
- Conditions
- vitiligo.Vitiligo
- Registration Number
- IRCT20210125050139N1
- Lead Sponsor
- Kerman University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Suffering from vitiligo
Age over 18 years
They have not received any treatment for vitiligo for 3 months before enrollment
Among the patients referred to Afzalipour Hospital, Besat Clinic and Dermatology Center
The diagnosis is made clinically by a dermatologist
Confirmation of the disease by means of examination with a Wood lamp
Exclusion Criteria
Uncontrolled systemic diseases
renal failure
history of allergy to calcineurin inhibitors and macrolides
age under 18
segmental vitiligo
involvement of more than 20% of the skin surface
history of autoimmune disease and use of other treatments
patient With a positive Coubern history
history of colloid and pregnancy and lactation
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method esion area. Timepoint: at base line and 1, 2, 3, 4, 5 and 6 months later. Method of measurement: Measure the diameters of the depigmented lesion using a ruler.;Disease activity. Timepoint: at base line and 1, 2, 3, 4, 5 and 6 months later. Method of measurement: Measurement of disease activity based on VIDA SCORE.;Percentage of improvement. Timepoint: at base line and 1, 2, 3, 4, 5 and 6 months later. Method of measurement: By clinical examination of the lesion and measuring the percentage of lesion healing compared to the primary lesion.
- Secondary Outcome Measures
Name Time Method Erythema. Timepoint: at base line and 1, 2, 3, 4, 5 and 6 months later. Method of measurement: by physical examination and classification of the severity of adverse effects to mild , moderate and severe.;Scaling. Timepoint: at base line and 1, 2, 3, 4, 5 and 6 months later. Method of measurement: by physical examination and classification of the severity of adverse effects to mild , moderate and severe.;Pruritis. Timepoint: at base line and 1, 2, 3, 4, 5 and 6 months later. Method of measurement: by physical examination and classification of the severity of adverse effects to mild , moderate and severe.;Secondary. Timepoint: at base line and 1, 2, 3, 4, 5 and 6 months later. Method of measurement: With clinical examination of the lesions and the presence of signs of infection such as purulent discharge and hotness.